Roth Capital Downgrades CorMedix (CRMD) to Neutral
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Price: $8.32 -0.95%
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 60
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 60
Join SI Premium – FREE
Roth Capital downgraded CorMedix (NYSE: CRMD) from Buy to Neutral with a price target of $7.50 (from $2.50).
For an analyst ratings summary and ratings history on CorMedix click here. For more ratings news on CorMedix click here.
Shares of CorMedix closed at $7.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades HCL Technologies (HCLT:IN) to Sell
- Morgan Stanley Downgrades Tryg A/S (TRYG:DC) (TGVSF) to Underweight
- Jefferies Downgrades Zealand Pharma A/S (ZEAL:DC) (ZEAL) to Hold
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
